As effective agents against thrombosis – platelet aggregation inhibitors – aspirin and clopidogrel are commonly used. Both alone or in combination have been shown to be effective in the primary and secondary prevention of thrombotic and embolic diseases based on evidence-based medical studies. However, there is a duality in everything, and it is well established that aspirin and clopidogrel can cause damage to the gastrointestinal tract. Aspirin can cause damage to the gastrointestinal mucosa regardless of the dose or duration of administration. Locally, it can destroy the barrier of the gastrointestinal mucosa; systemically, it affects prostaglandin synthesis and loses the repair function of the gastrointestinal mucosa. This, regardless of the route of administration, causes damage. Clopidogrel can inhibit platelet-derived growth factors and platelet-released vascular endothelial growth factor, thereby impeding neovascularization and affecting ulcer healing and mucosal repair effects. The clinical characteristics of aspirin injury to the gastrointestinal mucosa are: 1. The older the age, the higher the rate of injury. Age ≤ 65 years old is 1.1%; age ≥ 65 years old is 10.7% 2, common lesions: inflammation of various segments of the GI tract, GI erosion, GI ulcer, GI bleeding and perforation 3, most can be asymptomatic, common are: nausea, vomiting, epigastric discomfort or pain, diarrhea, vomiting blood, black stool, etc. 4, HP infection can aggravate the GI damage effect of aspirin long-term use of anti-platelet Prevention and countermeasures of gastrointestinal tract damage from long-term use of antiplatelet agents: 1, standardize the indications for antiplatelet therapy – weighing the pros and cons, it is strongly recommended that the primary prevention of thrombophilia by aspirin be eliminated. 2, there is no evidence of interaction between the simultaneous use of acid suppressants or gastric mucosal protective agents and antiplatelet agents, therefore, if the original history of gastrointestinal tract disease Therefore, if a person has a history of gastrointestinal disease and needs to take aspirin/clopyrrolidine for a long time, he should take acid suppressant or gastric mucosal protector at the same time, and do systematic gastrointestinal examination to prevent the recurrence of gastrointestinal disease. 3. 4. In some diseases that require the combination of antiplatelet agents, such as acute coronary syndrome and coronary stenting, when gastrointestinal symptoms occur, an antiplatelet agent can be stopped or an acid suppressant or gastric mucosal protector can be added. At the same time, the aggregation function of platelets should be closely tested. 5.For those with active bleeding, all anti-platelet agents should be discontinued first and the bleeding should be treated actively 6.For those with heavy bleeding, they should be kept in hospital for observation and treatment. If drug hemostasis or endoscopic hemostasis is ineffective, surgical hemostasis should be performed promptly.